Search

everythinglearnresearchcommunity

for

Search:↓

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

A woman's masculine features were caused by a rare ovarian tumor that produced male hormones.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Targeted cancer therapies often cause serious skin problems that need careful management.

PLD is an effective and safer alternative for treating breast cancer.

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

Some chemotherapy can cause permanent hair loss.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

The (+) enantiomer of YH239-EE effectively kills breast cancer cells.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Anxiety and depression were present but didn't affect overall quality of life in breast cancer patients on chemotherapy.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

Image analysis can effectively identify changes in scalps affected by chemotherapy-induced hair loss.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.

Growth factors and cytokines are important for hair growth and could potentially treat hair loss, but more research is needed to overcome challenges before they can be used in treatments.

Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.